全球細胞及基因治療市場成長機會及預測（至2030年）

摘要：細胞和基因治療市場

全球細胞和基因治療市場預計在2024年達到99.8億美元，預計到2030年將達到513.7億美元，2025年至2030年的複合年成長率為31.4%。臨床轉化方面的快速進展、基因修飾細胞療法的核准數量不斷增加以及體內基因治療的日益普及，正在推動整個細胞和基因治療（CGT）市場的持續成長。

關鍵市場趨勢與洞察

• 北美預計在 2024 年佔據全球細胞和基因治療市場最大的收入佔有率，這得益於加快的監管流程、強大的創業融資以及早期採用基於結果的報銷模式。
• 在美國，隨著 CAR-T 療法、基因編輯療法和體內基因療法的核准不斷增加，腫瘤學和罕見遺傳疾病領域的商業化進程正在加速。
• 按治療類型分類，基因修飾細胞療法將在 2024 年佔據主導地位，這反映出其在骨髓惡性腫瘤中的高普及率以及二線治療核准的不斷擴大。
• 在基因治療市場，病毒載體、脂質奈米顆粒和基因組編輯技術的進步推動了生物遞送平台的快速發展。
• 亞太地區正在崛起成為成長最快的地區，這得益於日本和中國不斷加快的法規結構建設以及國內製造業投資的增加。

製造自動化、智慧工廠和數位化品質系統的快速發展進一步增強了細胞和基因治療市場的擴充性。隨著監管政策的日益明朗和報銷模式的日益成熟，預計到預測期結束時，細胞和基因治療（CGT）市場將從利基創新轉變為主流治療支柱。

成長促進因素：細胞和基因治療市場

細胞和基因治療市場受到多種結構性成長因素的驅動，這些因素正在塑造其發展進程。

首先，基因組編輯工具、病毒載體和遞送平台的快速創新正在加速臨床成功率的提升。這些進步正將基因治療市場從治療罕見疾病擴展到治療更常見的疾病。

其次，諸如RMAT、PRIME和有條件核准等監管加速機制顯著縮短了研發週期。這種監管支持正在提高CGT治療市場的資本效率和投資報酬率。

第三，透過自動化和數位化的製造流程轉型正在克服傳統的擴充性限制。智慧工廠和人工智慧驅動的製程控制正在降低變異性，並實現細胞和基因治療市場中穩定的商業化生產。

第四，不斷發展的報銷模式，包括按效果付費合約和分期付款，正在緩解支付方對高額前期費用的抵觸情緒。這些框架正在擴大細胞和基因治療（CGT）市場的准入範圍，並穩定長期需求。

最後，創業融資和策略聯盟的增加正在推動產品線擴張和生態系統成熟，從而增強 CGT 治療市場持續成長的勢頭。

成長抑制因素：細胞和基因治療市場

儘管細胞和基因治療市場成長勢頭強勁，但該市場仍面臨一些限制因素，這些因素正在限制細胞和基因治療（CGT）市場的近期成長。

高昂的治療費用仍然是主要挑戰，尤其是對於一次性根治性治療而言。儘管報銷模式不斷演變，但由於經濟承受能力的擔憂，成本效益高的醫療保健系統仍然難以全面採用這些模式。

製造複雜性和產能限制仍然存在：雖然自動化提高了擴充性，但技術轉移風險、人才短缺和品管挑戰仍然影響著 CGT 治療市場。

本報告分析了全球細胞和基因治療市場，提供了六年收入預測（2025-2030 年）和全面的市場評估，包括研發管線發展、技術趨勢、監管和報銷模式、策略合作夥伴關係以及新興的上市策略。

目錄

調查範圍

• 市場定義、範圍和細分
• 分割
• 定義

成長環境：CGT治療市場的轉型

• 為什麼經濟成長變得越來越困難？
• 戰略必要性
• 三大戰略要務對CGT治療產業的影響

CGT治療市場生態系統

• 主要亮點
• 管道簡介
• 產品線概覽：細胞療法
• 研發管線概覽：基因療法和基因工程細胞療法
• 研發管線概覽：基因工程細胞療法
• 臨床試驗的挑戰與因應策略
• 製造挑戰及因應策略
• CGT連續體中的技術趨勢
• 策略夥伴關係與聯盟
• 北美：資本利得稅法規和贖回模式
• 歐洲：資本利得稅監理與贖回模式
• 亞太地區：資本利得稅法規與贖回模式
• 拉丁美洲和中東：資本利得稅法規和贖回模式
• 併購評估
• 創投評估
• 競爭環境
• 主要競爭對手

CGT治療市場成長要素

• 成長指標
• 成長促進因素
• 成長抑制因素
• 研究過程和方法
• 預測考量
• 收入預測
• 收入預測分析
• 按產品分類的收入預測
• 收入預測分析
• 按治療領域分類的收入預測
• 收入預測分析
• 按地區分類的收入預測
• 預測分析：按地區
• 收益分成
• 收入佔有率分析

成長要素：細胞療法

• 成長指標
• 收入預測
• 按來源分類的收入預測
• 預測分析

成長要素：基因改造細胞療法

• 成長指標
• 收入預測
• 按技術分類的收入預測
• 預測分析

成長要素：基因治療

• 成長指標
• 收入預測
• 按技術分類的收入預測
• 預測分析

發展機會

• 成長機會 1：加速核准的監理諮詢服務
• 成長機會2：利用人工智慧最佳化生物程序
• 成長機會3：建構一體化載體與質體生產中心
• 成長機會 4：利用區塊鏈和物聯網實現低溫運輸和第三方物流網路現代化
• 簡稱
• 成長機會帶來的益處和影響
• 下一步
• 圖表清單
• 免責聲明

Platform Innovation, Regulatory Maturity, and Global Capacity Expansion Are Catalyzing the Next Wave of Growth in Cell and Gene Therapy

The global CGT therapeutics market is transitioning from a niche, high-complexity segment into a mainstream, high-growth therapeutic class. Driven by scientific breakthroughs, accelerated regulatory pathways, and the entry of next-generation platforms-including in vivo CRISPR gene editing, allogeneic "off-the-shelf" cell therapies, and automated smart-factory bioprocessing-the market is projected to cross $50 billion by 2030 and reflect a greater than 30% CAGR between 2024 and 2030. This growth aligns with the expanding global disease burden: oncology indications continue to dominate CGT development, while rare genetic, neurological, hematologic, and ophthalmologic disorders fuel diversification into new high-value segments.

Pipeline momentum is unprecedented. In 2025, oncology remains the largest therapeutic focus, with hematologic malignancies accounting for the majority of trials and solid-tumor programs accelerating through improved tumor-microenvironment targeting and next-generation vectors. Rare diseases continue to anchor the CGT landscape-over two-thirds of rare-disease trials target rare cancers, while new programs are broadening into genetically linked common diseases such as Alzheimer's, cardiovascular disease, arthritis, and HIV. Approvals of CASGEVY™, Lyfgenia™, Elevidys™, Ryoncil™, Hemgenix(R), Roctavian(R), Vyjuvek(R), and emerging CNS and ophthalmology therapies demonstrate durable evidence that ex vivo and in vivo modalities offer curative potential across multiple disease categories.

Major scientific and operational inflection points are reshaping the sector. In vivo gene editing is rapidly progressing-Intellia's NTLA-2002 entered Phase III, Interius initiated the first in vivo CAR-T clinical pathway, and YolTech advanced LNP-delivered gene-editing into human studies. Parallel advances in automated manufacturing (e.g., Cellares Cell Shuttle™ receiving FDA AMT designation) and the rise of regional "IDMO Smart Factories" in the United States, Europe, and Japan signal a decisive move toward scalable, closed system, digitally orchestrated CGT production. Manufacturing readiness (MRL), AMT-qualified platforms, and cloud-enabled QA are becoming as important as clinical data for asset valuation.

Globally, the regulatory landscape is evolving in support of innovation.

North America leads with outcomes-based reimbursement models (CMS CGT Access Model with more than 33 states on board), accelerated approvals, and growing manufacturing capacity.

Europe advances through managed entry agreements and national value-based reimbursement, while APAC remains the fastest-growing geography, driven by Japan's expedited pathways, China's maturing NMPA frameworks, and South Korea's Rare Disease Act.

LATAM and the Middle East show early regulatory traction, led by the UAE and Saudi Arabia, though broad access remains limited.

Investment and M&A activity reflect a strategic focus on scalable platforms and next-generation delivery. The sector has shifted from megadeals to mid-sized "string-of-pearls" acquisitions-exemplified by Roche-Poseida, AbbVie-Capstan, Lilly-Verve, and Gilead-Interius-focused on in vivo editing, allogeneic CAR-T, and improved vector technologies. While venture investments have cooled relative to 2021 peaks, capital remains available for differentiated AAV capsids, LNPs, base/prime-editing technologies, and automated manufacturing platforms.

This research service provides a 6-year revenue forecast (2025 to 2030) and a comprehensive market evaluation across North America, Europe, APAC, MENASA, and Latin America, covering pipeline evolution, technology trends, regulatory and reimbursement models, strategic partnerships, and emerging GTM strategies. The analysis spans in vivo gene therapy, ex vivo gene therapy, gene-modified cell therapy, non-genetically modified cell therapy, and hybrid ex/in vivo modalities, each experiencing high double-digit growth. It identifies next-generation areas-such as allogeneic iPSC-derived therapies, base-editing, smart-factory automation, and in vivo CAR-T-as future growth engines.

Overall, the CGT therapeutics market is entering a period of accelerated commercialization, underpinned by robust late-stage pipelines, regulatory innovation, outcomes-based reimbursement, and transformative manufacturing technologies. Stakeholders that invest early in automated platforms, vector innovation, real-world evidence frameworks, and integrated global access strategies will be best positioned to capture growth in this rapidly expanding, high-impact therapeutic domain.

Report Summary: Cell And Gene Therapy Market

The global Cell & Gene Therapy Market size was estimated at USD 9.98 billion in 2024 and is projected to reach USD 51.37 billion by 2030, growing at a CAGR of 31.4% from 2025 to 2030. Rapid clinical translation, increasing approvals of gene-modified cell therapies, and expanding adoption of in vivo gene therapies are driving sustained growth across the cell and gene therapy (CGT) market.

Key Market Trends & Insights

• North America accounted for the largest revenue share of the global Cell And Gene Therapy Market in 2024, supported by accelerated regulatory pathways, strong venture funding, and early adoption of outcomes-based reimbursement models.
• In the United States, increasing approvals of CAR-T, gene-editing, and in vivo gene therapies are accelerating commercialization across oncology and rare genetic disorders.
• By therapy type, gene-modified cell therapies held the dominant position in 2024, reflecting strong uptake in hematologic malignancies and expanding second-line treatment approvals.
• The Gene therapy market is witnessing rapid momentum in vivo delivery platforms, driven by advancements in viral vectors, lipid nanoparticles, and genome-editing technologies.
• Asia Pacific is emerging as the fastest-growing region, supported by accelerated regulatory frameworks in Japan and China and increasing domestic manufacturing investments.

Market Size & Forecast

• 2024 Market Size: USD 9.98 Billion
• 2030 Projected Market Size: USD 51.37 Billion
• CAGR (2025-2030): 31.4%
• North America: Largest Market in 2024
• Asia Pacific: Fastest-Growing Market

The rapid evolution of manufacturing automation, smart factories, and digital quality systems is further strengthening the scalability of the CGT therapeutics market. As regulatory clarity improves and reimbursement models mature, the cell and gene therapy (CGT) market is expected to transition from niche innovation to a mainstream therapeutic pillar by the end of the forecast period.

Market Overview & Trends: Cell & Gene Therapy Market

The Cell & Gene Therapy Market is transitioning from experimental innovation to an integrated therapeutic ecosystem built on platform scalability, regulatory convergence, and commercial readiness. Historically constrained by high costs, manufacturing complexity, and reimbursement uncertainty, the cell and gene therapy (CGT) market is now benefiting from structural shifts that support broader adoption.

One of the most significant trends shaping the CGT therapeutics market is the shift from autologous, batch-based manufacturing toward automated, closed-system platforms. Smart factories, digital batch records, and AI-driven process analytics are reducing production timelines, improving consistency, and lowering cost of goods. These advancements are enabling developers to move beyond ultra-rare indications and address larger patient populations.

Another defining trend in the Gene therapy market is the rapid growth of in vivo delivery platforms, including AAV and lipid nanoparticle-based systems. These approaches reduce logistical complexity and expand treatment accessibility compared to ex vivo therapies. Concurrently, hybrid models combining cell and gene engineering are emerging as next-generation innovation zones within the Cell And Gene Therapy Market.

Regulatory frameworks are also evolving. Agencies such as the FDA, EMA, and PMDA are refining guidance on comparability, long-term follow-up, and accelerated approvals. Programs such as RMAT, PRIME, and Sakigake are compressing development timelines by 12-18 months, improving capital efficiency across the cell and gene therapy (CGT) market.

On the commercial front, reimbursement models are shifting toward outcomes-based agreements and annuity-style payments. These mechanisms are addressing payer concerns around high upfront costs while enabling sustainable access. Collectively, these trends are redefining the operating model of the CGT therapeutics market, positioning it for sustained long-term growth.

Scope of Analysis: Cell and Gene Therapy Market

This analysis examines the global Cell And Gene Therapy Market with a comprehensive assessment of industry structure, technology evolution, and commercial dynamics. The study period spans 2021-2030, with 2024 as the base year and 2025-2030 as the forecast period. All market values are expressed in US dollars.

The scope covers therapeutic modalities within the cell and gene therapy (CGT) market, including non-genetically modified cell therapies, gene-modified cell therapies, and gene therapies. DNA- and RNA-based therapeutics outside regenerative medicine frameworks are excluded. The CGT therapeutics market assessment includes approved products and advanced pipeline assets expected to reach commercialization during the forecast horizon.

Geographic coverage includes North America, Europe, Asia-Pacific, Latin America, and the Middle East, reflecting both mature and emerging adoption cycles in the Gene therapy market. Regional analysis focuses on regulatory maturity, reimbursement readiness, and ecosystem development rather than segment-level revenue attribution.

Methodologically, the Cell & Gene Therapy Market evaluation integrates primary expert interviews, pipeline tracking, regulatory analysis, and secondary data from clinical trial databases, financial disclosures, and industry associations. Revenue forecasting incorporates product lifecycle assumptions, approval probabilities, and pricing evolution, while excluding granular segment-level revenue splits to maintain consistency and reliability.

Revenue & Spending Forecast: Cell And Gene Therapy Market

The global Cell & Gene Therapy Market is exhibiting a steep and sustained growth trajectory, driven by accelerating commercialization of advanced therapies, expanding clinical pipelines, and improving regulatory and reimbursement clarity. According to the revised forecast, global market revenue increased from USD 5.73 billion in 2022 to USD 9.98 billion in 2024, reflecting rapid early-stage adoption across oncology and rare genetic disorders.

During the forecast period, the cell and gene therapy (CGT) market is expected to scale sharply, reaching USD 51.37 billion by 2030, expanding at a robust compound annual growth rate (CAGR) of 31.4%. This growth curve highlights the transition of the CGT therapeutics market from pilot-scale commercialization toward broader clinical and geographic penetration.

Revenue acceleration is primarily supported by rising approvals of gene-modified cell therapies, increasing uptake of in vivo gene therapies, and growing confidence in outcomes-based reimbursement models. As therapies move from ultra-rare indications into larger patient populations, spending momentum across the Gene therapy market is expected to intensify.

Investment activity across manufacturing automation, viral vector capacity expansion, and digital quality systems is further reinforcing long-term revenue growth. Overall, the Cell And Gene Therapy Market is positioned to evolve into a core pillar of advanced therapeutics by the end of the forecast period, with revenue growth reflecting both clinical maturity and ecosystem scalability.

Market Segmentation Analysis: Cell & Gene Therapy Market

The Cell & Gene Therapy Market is segmented based on therapeutic modality, therapeutic area, delivery approach, and geography, reflecting the multidimensional nature of the cell and gene therapy (CGT) market ecosystem.

By therapeutic modality, the CGT therapeutics market includes non-genetically modified cell therapies, gene-modified cell therapies, and gene therapies. Gene-modified cell therapies, particularly CAR-T and TCR-based platforms, currently represent the most commercially mature segment, supported by strong oncology uptake. Gene therapies delivered via viral and non-viral vectors are expanding rapidly as in vivo approaches gain regulatory and clinical validation.

Therapeutic area segmentation highlights oncology as the dominant focus within the Gene therapy market, accounting for the largest share of pipeline activity and commercial approvals. Hematologic malignancies remain central; however, solid tumors, neurological disorders, cardiovascular diseases, and inherited metabolic conditions are increasingly targeted. This diversification is broadening the addressable market for the Cell And Gene Therapy Market.

From a delivery perspective, ex vivo therapies continue to dominate approved products, but in vivo delivery is gaining momentum due to simplified logistics and scalability advantages. Hybrid in vivo-ex vivo platforms are emerging as innovation frontiers within the cell and gene therapy (CGT) market.

Geographically, North America leads in commercialization and reimbursement innovation, while Europe emphasizes structured access through managed entry agreements. Asia-Pacific is witnessing accelerated regulatory approvals and localized manufacturing investments. Overall, segmentation trends indicate a gradual shift toward scalable, platform-based solutions across the CGT therapeutics market.

Growth Drivers: Cell & Gene Therapy Market

The Cell & Gene Therapy Market is propelled by multiple structural growth drivers shaping the evolution of the cell and gene therapy (CGT) market.

First, rapid innovation in genome-editing tools, viral vectors, and delivery platforms is accelerating clinical success rates. These advancements are expanding the therapeutic reach of the Gene therapy market beyond rare diseases into more prevalent conditions.

Second, regulatory acceleration mechanisms such as RMAT, PRIME, and conditional approvals are significantly reducing development timelines. This regulatory support enhances capital efficiency and improves return on investment across the CGT therapeutics market.

Third, manufacturing transformation through automation and digitalization is addressing historical scalability constraints. Smart factories and AI-enabled process control are reducing variability and enabling consistent commercial output within the Cell And Gene Therapy Market.

Fourth, evolving reimbursement models-including outcomes-based agreements and installment payments-are mitigating payer resistance to high upfront costs. These frameworks are unlocking broader access and stabilizing long-term demand in the cell and gene therapy (CGT) market.

Finally, increasing venture funding and strategic partnerships are fueling pipeline expansion and ecosystem maturity, reinforcing sustained growth momentum across the CGT therapeutics market.

Growth Restraints: Cell & Gene Therapy Market

Despite strong momentum, the Cell & Gene Therapy Market faces several constraints that temper near-term growth in the cell and gene therapy (CGT) market.

High therapy prices remain a primary challenge, particularly for one-time curative treatments. Even with evolving reimbursement models, affordability concerns continue to limit adoption in cost-sensitive healthcare systems within the Gene therapy market.

Manufacturing complexity and capacity constraints also persist. While automation is improving scalability, technology transfer risks, workforce shortages, and quality control challenges still impact the CGT therapeutics market.

Regulatory heterogeneity across regions creates uncertainty for global commercialization. Differences in evidence requirements and long-term follow-up obligations slow market entry for the Cell And Gene Therapy Market in certain geographies.

Finally, long-term safety and durability concerns necessitate extended post-marketing surveillance, increasing development costs and payer scrutiny. Addressing these barriers is essential for sustaining long-term growth in the cell and gene therapy (CGT) market.

Competitive Landscape: Cell & Gene Therapy Market

The Cell & Gene Therapy Market features a dynamic and fragmented competitive environment comprising large pharmaceutical companies, specialized biotechnology firms, and CDMOs. Market leaders are leveraging platform-based strategies to scale across multiple indications within the CGT therapeutics market.

Major players focus on expanding portfolios through targeted acquisitions, licensing agreements, and strategic collaborations. M&A activity increasingly emphasizes next-generation delivery platforms, in vivo gene editing, and automated manufacturing capabilities, reflecting evolving priorities in the Gene therapy market.

Biotechnology firms continue to drive innovation, particularly in gene-modified cell therapies and novel vector technologies. Meanwhile, CDMOs are transitioning from service providers to integrated partners offering regulatory-ready capacity, digital manufacturing, and logistics support across the cell and gene therapy (CGT) market.

Competitive differentiation is increasingly defined by manufacturing readiness, regulatory execution, and payer engagement capabilities rather than clinical innovation alone. As competition intensifies, ecosystem collaboration will remain critical to sustaining leadership in the Cell and Gene Therapy Market.

Table of Contents

Research Scope

• Market Definition, Scope, and Segmentation
• Segmentation
• Definitions

Growth Environment: Transformation in the CGT Therapeutics Market

• Why Is It Increasingly Difficult to Grow?
• The Strategic Imperative
• The Impact of the Top 3 Strategic Imperatives on the CGT Therapeutics Industry

Ecosystem in the CGT Therapeutics Market

• Key Highlights
• Pipeline Snapshot
• Pipeline Snapshot: Cell Therapy
• Pipeline Snapshot: Gene Therapy and Genetically Modified Cell Therapies
• Pipeline Snapshot: Gene-Modified Cell Therapy
• Clinical Trial Challenges and Strategies to Overcome
• Manufacturing Challenges and Strategies to Overcome
• Technology Trends Across the CGT Continuum
• Strategic Partnerships and Collaborations
• North America: CGT Regulatory & Reimbursement Models
• Europe: CGT Regulatory & Reimbursement Models
• Asia-Pacific: CGT Regulatory & Reimbursement Models
• LATAM and Middle East: CGT Regulatory & Reimbursement Models
• M&A Assessment
• Venture Financing Assessment
• Competitive Environment
• Key Competitors

Growth Generator in CGT Therapeutics Market

• Growth Metrics
• Growth Drivers
• Growth Restraints
• Research Process and Methodology
• Forecast Considerations
• Revenue Forecast
• Revenue Forecast Analysis
• Revenue Forecast by Product
• Revenue Forecast Analysis
• Revenue Forecast by Therapeutic Area
• Revenue Forecast Analysis
• Revenue Forecast by Region
• Forecast Analysis by Region
• Revenue Share
• Revenue Share Analysis

Growth Generator: Cell Therapy

• Growth Metrics
• Revenue Forecast
• Revenue Forecast by Source
• Forecast Analysis

Growth Generator: Gene-Modified Cell Therapy

• Growth Metrics
• Revenue Forecast
• Revenue Forecast by Technology
• Forecast Analysis

Growth Generator: Gene Therapy

• Growth Metrics
• Revenue Forecast
• Revenue Forecast by Technology
• Forecast Analysis

Growth Opportunity Universe

• Growth Opportunity 1: Regulatory Advisory Services for Accelerated Approvals
• Growth Opportunity 2: AI-Driven Bioprocess Optimization
• Growth Opportunity 3: Create Integrated Vector and Plasmid Manufacturing Hubs
• Growth Opportunity 4: Modernize Cold Chain and 3PL Networks with Blockchain and IoT
• Abbreviations
• Benefits and Impacts of Growth Opportunities
• Next Steps
• List of Exhibits
• Legal Disclaimer